A

Athenex Inc
F:2MT

Watchlist Manager
Athenex Inc
F:2MT
Watchlist
Price: 0.12 EUR Market Closed
Market Cap: 715.7m EUR
No Stock Splits Found

We don't have any information about 2MT's stock splits.

Global
Stock Splits Monitor

Date Company Split Pre-Split Price Post-Split Price
May 8, 2025
88 Energy Ltd
ASX:88EDA
1-for-25
/25
0.001 0.025 AUD 0.025 0.025 AUD
May 6, 2025
F
Future Bright Mining Holdings Ltd
HKEX:2957
1-for-40
/40
1.3 1.3 HKD 1.3 1.3 HKD
May 6, 2025
Sharplink Gaming Ltd
NASDAQ:SBET
1-for-12
/12
0.41 4.92 USD 3.84 3.84 USD
May 6, 2025
V
Villa Kunalai PCL
SET:KUN
26-for-25
x1.04
1.19 1.1347 THB 1.2 1.2 THB
May 6, 2025
Z
ZheJiang Yayi Metal Technology Co Ltd
SZSE:301113
1-for-1
x1
25.0201 18.7708 CNY 20.24 20.24 CNY
Load More

Athenex Inc
Glance View

Market Cap
715.7m EUR
Industry
Biotechnology

Athenex, Inc. is a biopharmaceutical company, which engages in the discovery, development and commercialization of novel therapies for the treatment of cancer. The company is headquartered in Buffalo, New York and currently employs 652 full-time employees. The company went IPO on 2017-06-14. The Company’s platforms include Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. Oncology Innovation Platform is engaged in research and development of its drugs. Global Supply Chain Platform is engaged in supplying active pharmaceutical ingredient to clinical and commercial efforts. Commercial Platform includes specialty pharmaceuticals business, and manufacture and marketing of products. The Company’s product pipeline includes Orascovery, Src Kinase Inhibition, Cell Therapy and Arginine Deprivation Therapy. Its lead product candidate Orascovery platform technology is based on the oral P-gp pump inhibitor molecule, encequidar. The Src Kinase inhibition platform technology is based on small molecule compounds including the inhibition of the activity of Src Kinase and the inhibition of tubulin polymerization.

2MT Intrinsic Value
Not Available
A
Back to Top